Cutaneous Toxicities of Molecular Targeted Therapies.

about

Cutaneous Toxicities of Molecular Targeted Therapies.

Item

http://www.wikidata.org/entity/Q41541640

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Cutaneous Toxicities of Molecular Targeted Therapies.

@en

type

Item

label

Cutaneous Toxicities of Molecular Targeted Therapies.

@en

prefLabel

Cutaneous Toxicities of Molecular Targeted Therapies.

@en

P1476

Cutaneous Toxicities of Molecular Targeted Therapies.

@en

P2093

Bogdan Georgescu

http://www.w3.org/2001/XMLSchema#string

Daniela Zob

http://www.w3.org/2001/XMLSchema#string

Laura Papagheorghe

http://www.w3.org/2001/XMLSchema#string

Oana Catalina Toma

http://www.w3.org/2001/XMLSchema#string

Raluca Ioana Mihaila

http://www.w3.org/2001/XMLSchema#string

P2860

Cutaneous complications of molecular targeted therapy used in oncology

Acneiform Rash Induced by EGFR Inhibitors: Review of the Literature and New Insights

Treatment strategies of epidermal growth factor receptor inhibitor-induced skin toxicities: pre-emptive or reactive?

Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials.

The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials.

Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.

EGFR inhibitor-induced skin reactions: differentiating acneiform rash from superimposed bacterial infections.

Cutaneous manifestations of nontargeted and targeted chemotherapies.

Correlation Between the Severity of Cetuximab-Induced Skin Rash and Clinical Outcome for Head and Neck Cancer Patients: The RTOG Experience.

Doxycycline for prevention of erlotinib-induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy: A randomized, open-label trial.

P304

48-54

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Dana Lucia Stănculeanu

P577

2017-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28878837

http://www.w3.org/2001/XMLSchema#string

P932

5574072

http://www.w3.org/2001/XMLSchema#string

Cutaneous Toxicities of Molecular Targeted Therapies.

about

Cutaneous Toxicities of Molecular Targeted Therapies.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P433

P478

P50

P577

P698

P932

P1433

P1476

P2093

P2860

P304

P31

P433

P478

P50

P577

P698

P932